Introduction
Retinoblastoma is the most common primary intraocular malignancy in children; its incidence rate is 1 in 14,000 to 20,000 livebirths. 1 However, compared with other pediatric malignancies, retinoblastoma is rare, comprising 3% to 4% of all pediatric cancers. 2 It is a tumor of the developing retina that arises from primitive retinal stem cells or cone precursor cells associated with inactivation of both alleles of the tumor suppressor gene RB1. Major advances, such as our understanding of the molecular biology of the tumor and the development of targeted therapy, have improved survival rates in developed countries. 3 In the United States, the 5-year overall survival rate is 97%. 4 Much of this success is due to the benefits of effective treatments, including chemotherapy, focal or consolidation therapy, external beam radiotherapy, and surgical enucleation (Table 1) . 5 With early diagnosis and aggressive, multimodal treatment strategies, near-complete cure rates are possible, and many patients retain functional vision in at least 1 eye. However, in developing nations, where access to health care is limited, retinoblastoma can cause blindness and death. 6 Among the mainstay treatments for retinoblastoma are intravenous chemotherapy (involving agents associated with significant toxicities), surgical enucleation, external beam radiotherapy, or all 3 options, poten-tially result in disfigurement and secondary malignancies. However, in recent years, an ongoing evolution has taken place, where treatment is being geared toward more targeted therapy and local medication delivery. Local delivery increases exposure to intraocular target areas, reduces overall systemic exposure and harmful late effects, and improves effectiveness and rates of tolerability. The introduction of intra-arterial and intravitreal chemotherapy has resulted in a change in treatment algorithms and improved outcomes, with their possibility of ocular salvage and maintenance of vision. 7 Preclinical models that simulate human disease are needed for rare childhood cancers such as retinoblastoma because not enough patients with the disease exist for large-scale, multicenter clinical trials. Despite the lack of clinical trials, rates of survival and ocular preservation have improved. 7 In vitro studies and animal models remain instrumental in understanding biological mechanisms and assessing safety and effectiveness of the treatment options for this disease. [8] [9] [10] Examples of emerging therapies under investigation for retinoblastoma are alternative chemotherapeutic agents, molecularly targeted therapies, and novel drug-delivery systems.
Concepts and Principles of Treatment
The goal of treatment in retinoblastoma is the elimination of the tumor while concurrently minimizing collateral injury to other tissues. The priorities in management are (1) preventing metastasis, (2) reducing the risk of long-term secondary tumors (eg, osteosarcoma, soft-tissue sarcoma), (3) saving the eye, and (4) preserving vision.
11 Caring for a patient with retinoblastoma must be a multidisciplinary effort involving pediatric oncologists, ocular oncologists, radiation oncologists, ocular pathologists, and geneticists to optimize treatment outcomes.
Treatment depends on tumor stage, laterality and number of tumor foci (unifocal, unilateral, multifocal, or bilateral), the localization and size of tumors within the eye, presence of vitreous seeding, age and health of the child, and the family's wishes. 12 The type of management depends on the tumor classification, which is based on 2 systems: the International Classification of Retinoblastoma 13 used to predict success of chemoreduction 14 and the tumor, node, and metastasis classification of the American Joint Committee on Cancer 15 for tumor staging ( Table 2) . Location of the tumor in rela- tion to the optic disc and macula is important in the clinical evaluation because it largely affects the visual prognosis. Involvement of certain tissues in and around the eye, including the optic nerve, choroid, iris, sclera, and orbit, increase the likelihood of tumor metastasis. 16 In children, unilateral retinoblastoma is differently managed than bilateral tumors. In general, unilateral cases are the result of sporadic mutations, whereas bilateral cases are typically multifocal, hereditary, and occur in patients carrying a germline RB1 mutation, thus placing them at risk for other malignancies (eg, intracranial neuroblastic tumors [pinealoblastoma in trilateral retinoblastoma]). In general, unilateral tumors can be managed with focal therapy alone; chemoreduction, intra-arterial chemotherapy with focal therapy, or both; or enucleation. If genetic testing is not performed, then patients with unilateral disease require close follow-up of the unaffected eye to exclude bilateral involvement. Alternatively, treatment for bilateral tumors will depend on the extent of tumor in each eye. In asymmetric disease, an attempt is made to salvage the eye with less severe disease. One may consider giving patients systemic intravenous chemoreduction as initial therapy to treat both eyes as well as to prevent metastasis and associated secondary tumors or to use local (intra-arterial) chemotherapy with focal treatment. 7, 17, 18 Initial chemotherapy in retinoblastoma can be given either systemically (intravenous) or locally (directly through the ophthalmic artery/intra-arterial). Chemoreduction is then usually followed by consolidation, which is achieved by focal therapy (eg, laser photocoagulation, thermotherapy, cryotherapy, plaque brachytherapy). Focal therapy may be employed as the only or initial therapy for small retinoblastoma tumors located away from the fovea and optic nerve (group A); it is often used for tumor consolidation in retinoblastoma following chemoreduction for more advanced (groups B-D) tumors. Surgical removal of the eye or enucleation is reserved for very advanced (group E) cases.
Management
Chemotherapy Intravenous: Systemic chemotherapy generally involves a combination 2-, 3-, or 4-drug regimen delivered through an intravenous catheter. Three classes of agents are commonly employed: DNA-crosslinking agents (carboplatin, cisplatin), DNA topoisomerase 2 inhibitors (etoposide, topotecan, teniposide) and Vinca alkaloids (vincristine; Fig 1) . The most commonly used regimen is vincristine/etoposide/carboplatin.
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Chemoreduction via systemic chemotherapy was introduced as a management option for retinoblastoma in the mid-1990s following preliminary observations that systemic chemotherapy delivered prior to external beam radiotherapy contributed to tumor control and ocular salvage. 19 A subsequent study on eyes treated with chemoreduction combined with focal treatments (cryotherapy, thermotherapy, or plaque radiotherapy) demonstrated tumor regression and decreased need for additional external beam radiotherapy and enucleation. 20 This was a major advancement in management because it was evident that satisfactory tumor control could be attained with systemic chemotherapy while saving the eye and avoiding the adverse events of external beam radiotherapy. 20 Using the International Classification of Retinoblastoma, treatment success was found in 100% of group A eyes, 93% of group B eyes, 90% of group C eyes, and 48% group D eyes.
14 This launched the so-called "systemic chemotherapy era" (1990s to 2006); however, with the advent of local routes of administration (intra-arterial and intravitreal), use of systemic chemotherapy has decreased in recent years.
14 Intravenous chemotherapy is indicated as initial therapy for bilateral advanced disease in which attempts are made to salvage both eyes. Many centers use systemic chemotherapy in bilateral (germline) retinoblastoma for intraocular retinoblastoma control as well as to prevent metastasis, reduce the likelihood of the development of pineoblastoma, and to reduce the long-term risk of secondary cancers. 17, 18 Systemic chemotherapy is also utilized as adjuvant treatment to prevent metastasis following enucleation in patients with optic nerve invasion posterior to the lamina cribrosa, massive choroidal invasion, or any combination of optic nerve and choroidal invasion. 21 The treatment regimens used include vincristine/etoposide/carboplatin, vincristine/doxorubicin/idarubicin/cyclophosphamide, or hybrid regimens, typically delivered monthly for 6 to 9 months. 22 A major obstacle to use of intravenous chemotherapy in retinoblastoma is the blood-retina barrier, which limits the entry of some chemotherapeutic agents into the eye, thereby reducing their efficacy. 23 Systemic chemotherapy for retinoblastoma is generally safe and effective, but it is not without adverse events, such as neurotoxicity, hyponatremia, nephrotoxicity, ototoxicity, and secondary leukemia. Treatment failure in the form of persistent vitreous seeds, subretinal seeds, and intraretinal tumors following therapy have been attributed to the inability of the treatment drugs to reach the tumor. 24 Tumor resistance or unresponsiveness to chemotherapy is thought to occur more often in well-differentiated tumors, presumably because cells are not cycling, so they are less likely to respond to treatment modalities affecting cell division. 25 Intra-Arterial: In the late 1980s, melphalan was found to be effective for the management of retinoblastoma in vitro. 26 Yamane et al 27 and Suzuki et al 28 then began to treat patients with intracarotid artery melphalan, developing a technique to safely and effectively cannulate the ophthalmic artery for chemotherapy infusion. In the United States, intra-arterial chemotherapy (IAC) was initially used by Abramson et al. 29 IAC involves transfemoral catheterization with advancement into the ophthalmic artery, which is where melphalan, topotecan, or carboplatin is infused. The medication is slowly delivered for 30 minutes in a pulsatile fashion with care to not occlude the artery and to minimize reflux into the internal carotid artery. Most patients receive 3 monthly sessions. Melphalan is the most frequently used agent, with topotecan added if extensive vitreous seeding is present.
Generally, IAC is employed for unilateral or nongermline retinoblastoma, recurrent tumors following previous intravenous chemotherapy or plaque radiotherapy, recurrent subretinal seeds involving at least 2 quadrants, recurrent vitreous seeds, or, if the patient wishes to avoid systemic therapy, enucleation can be considered if consent is obtained. In a 5-year experience with IAC, complete regression was achieved for solid tumors in 94%, for subretinal seeds in 95%, and for vitreous seeds in 87% of study patients. 30 In recent years, globe-salvage results (85%-94% globe salvage rate in group D tumors with primary IAC) have been reported in study patients with advanced retinoblastoma. 30, 31 In some centers, most group D eyes are primarily treated with IAC, and, on occasion, group D and E eyes are managed with combined intravenous chemotherapy followed by intra-arterial chemotherapy -particularly if the patient has advanced bilateral disease or disease in a single eye. 7 Fair success has been reported in group E tumors with total retinal detachment cautiously managed with initial IAC. 32, 33 Treatment of more advanced disease with initial IAC has also not been shown to compromise survival rates. 7 After adequate reduction is visualized and subretinal fluid is resolved, complete consolidation with either thermotherapy or cryotherapy and supplemental intravitreal chemotherapy after IAC are commonly performed. Consolidation is generally performed during the second or third cycle of chemoreduction.
In infants younger than 3 months who weigh less than 7 kg, IAC is initially deferred to allow the femoral artery to grow before attempting catheterization. In such cases, patients are treated with 1 to 2 doses of single-agent carboplatin as bridge therapy before definitive IAC. 34 Reports of high rates of efficacy of IAC abound, but studies also exist on its associated ocular toxicities. [35] [36] [37] Use of intra-arterial infusion of melphalan and carboplatin compromise the ocular vasculature in nonhuman primates and induces inflammation and leukostasis in human retinal endothelial cells. 35, 36 Other complications include vitreous hemorrhage, microemboli to the retina and choroid, myositis, eyelid edema, orbital congestion with resulting dysmotility, choroidal atrophy, optic atrophy, ophthalmic artery stenosis, and branch-retinal artery occlusion resulting in blindnesss. 37 A major drawback to this therapy is that only skilled neurosurgeons and/or interventional radiologists at major cancer centers can treat patients using IAC. 38 The therapy is also expensive. 39 In developing countries, IAC is not available or is too costly, so enucleation as initial therapy is still a mainstay of treatment for advanced retinoblastoma. 40 In addition, a study has shown that initial chemotherapy prior to enucleation for advanced retinoblastoma can mask pathological evidence of tumor extension, thus leading to reduced surveillance and the undertreatment of high-risk disease -thereby increasing the risk of metastatic death. 41 Intravitreal: The major question encountered in the management of retinoblastoma is how to treat subretinal and vitreous seeds of tumor unresponsive to laser treatment, conventional chemoreduction therapy, or IAC. 24 Treatment of vitreous seeds is challenging due to lack of vasculature in the vitreous. Another route of administration developed to address this problem is the intravitreal method, which involves injecting the therapeutic agent into the vitreous cavity of the eye through the pars plana under aseptic precautions.
Although health care professionals were initially skeptical of injecting drugs through the sclera into the vitreous for fear of tumor spread along needle tracks, techniques for safe and effective intravitreal injections have been developed. Intraocular pressure is first lowered prior to the injection. A small-volume dose of melphalan, topotecan, or a combination of both is injected into the eye using a fine needle (30-or 32-gauge) and the needle is frozen with a cryoprobe as it is withdrawn from the eye to prevent tumor seeding. 42 The first-line indication for intravitreal chemotherapy includes vitreous seeds refractory to standard therapy and recurrent vitreous seeds after previous therapy. 43, 44 In an analysis of 57 eyes with viable recurrent vitreous seeds, intravitreal melphalan led to eye salvage in 51% of eyes after 10 years of follow-up; no cases of extraocular extension were reported during that time. 45 A systematic review showed that proper technique does not increase the risk of tumor spread. 46 Treatment of retinoblastoma with recurrent vitreous seeds has been reported to have a success rate of 83%. 47 The number of injections depends on the response, and 6 injections delivered weekly or biweekly is recommended. Reported adverse events include transient vitreous hemorrhage, chorioretinal atrophy, and extraocular tumor spread. 42, 48, 49 Melphalan is the most commonly used drug for intravitreal injections. Although it caused no systemic toxicity in humans or rabbits, melphalan did result in significant retinal toxicity at high doses and lower but safer doses only achieved incomplete tumor control. 42, 50 Periocular: Chemotherapeutic agents may be periocularly injected, either as subconjunctival or subtenon. Periocular injection enables transcleral drug delivery, using the large surface area of the sclera and its high permeability to small molecules without the danger of puncturing the globe. 51 Periocular chemotherapy achieves levels within the vitreous rapidly and at levels 6 to 10 times higher than the intravenous route. 52 In general, periocular injection of chemotherapeutic agents has been used for retinoblastoma control as an adjunct to systemic chemotherapy and, on occasion, to treat tumor recurrence. Either carboplatin or topotecan can be employed. The first-line indications for periocular chemotherapy are bilateral advanced group D or E eyes in which a higher local dose of chemotherapy is needed, treatment of vitreous seeds, and recurrent localized tumor. Subtenon chemotherapy using carboplatin can increase tumor control, especially if it is coupled with intravenous chemoreduction. Subtenon carboplatin showed initial favorable results as single therapy, but long-term follow-up revealed a high failure rate as initial treatment; therefore, it should be combined with other therapeutic approaches. 53 Complications of periocular chemotherapy include orbital and eyelid edema, ecchymosis, orbital fat atrophy, muscle fibrosis leading to strabismus, and optic atrophy. [53] [54] [55] Because of its significant toxic effects, periocular chemotherapy is rarely used in current practice.
Focal Therapy
Thermotherapy/Transpupillary Thermotherapy: This type of focal therapy uses an 810-nm diode laser directly on the tumor to heat it up to subcoagulation temperatures of 42 to 60 °C to induce a cytotoxic effect. It is used for local control and for small (< 4.5-mm base and 2.5-mm thickness) tumors posteriorly located to the equator of the globe. In cases of macular or juxtapapillary tumors, consolidation should be performed with caution so as to protect the optic disc and neurosensory papillomacular bundle. The tumor may be observed while on chemoreduction and, if unresponsive, foveal-sparing thermotherapy may be administered. In an analysis of 68 macular retinoblastomas treated with chemoreduction, tumor recurrence occurred in 17% of those consolidated with foveal-sparing thermotherapy compared with 35% of those observed without consolidation. 56 Complications of transpupillary thermotherapy include iris atrophy, focal cataracts, tumor seeding into the vitreous, and retinal fibrosis, transition, and vascular occlusion.
Laser Photocoagulation: This type of therapy uses an 520-nm argon laser to coagulate the blood supply of the tumor by generating heat with temperatures in excess of 65 °C within the treatment spot. Direct photocoagulation to the tumor must be avoided. A second mechanism occurring around the ring of tissue beyond the laser spot is the increase in temperature to a thermotherapeutic range (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) o C). In this region, synergism exists with carboplatin, so this laser treatment is typically performed within 24 hours of the intravenous chemotherapy cycle. Small posterior tumors without seeding respond well to laser photocoagulation. It is not used for tumors impinging on the fovea, because of the risk of compromising a patient's central vision. In such cases, some form of chemotherapy can be used to shrink the tumor prior to the start of definitive laser treatment. Photocoagulation is also used to treat tumor-associated retinal neovascularization. Complications include vitreous seeding if the laser power is too high, and retinal fibrosis, traction, and vascular occlusion.
Cryotherapy: Cryotherapy involves a cryoprobe by which liquid nitrogen is delivered and directly applied to the outer surface of the sclera adjacent to the tumor. It is suitable for small (< 3.5-mm base and < 2-mm thickness) tumors anteriorly located to the equator of the globe. Complications of cryotherapy include retinal tears and detachment, proliferative vitreoretinopathy, and chorioretinal atrophy.
Plaque Brachytherapy: This type of treatment refers to implantation of radioactive material on the sclera over the base of the tumor. Tissue absorption of ionizing radiation causes DNA damage and cell death. Because retinoblastoma has a high rate of proliferating cells, it is quite radiosensitive. Brachytherapy is used for solitary, medium-sized tumors (6-15 mm and > 3 mm from the optic disc or fovea) and, if little subretinal fluid is present, plaque radiotherapy can generally be used to achieve tumor control. Iodine-125 and ruthenium-106 isotopes are the most common source of radiation currently used in brachytherapy for retinoblastoma to deliver 40 to 45 Gy to the apex of the tumor. In addition to treatment for retinoblastoma, ocular brachytherapy is commonly used for uveal melanoma, in which a clinician uses a similar surgical technique of plaque application of suturing to the episcleral surface but uses a lower dose of radiation. Complications of plaque brachytherapy include radiation retinopathy and optic neuropathy. 18 Consolidation alone may be used in group A and B tumors. Bilateral cases with small, extrafoveal tumors can be managed with focal treatments alone. In asymmetric disease, a single eye can be managed with focal techniques and the other with enucleation or intra-arterial chemotherapy with or without systemic chemotherapy. 7 The desired end point is tumor regression in the form of a completely calcified tumor (type 1 regression) or a flat chorioretinal scar (type 4 regression).
Enucleation
Enucleation remains a favored approach in cases of extensive retinoblastoma with buphthalmos, neovascular glaucoma, aqueous seeding, and transcleral extension (advanced group E eyes) -particularly for unilateral cases with no likelihood of functional vision. 6 Surgery involves careful removal of the eye with minimal globe trauma to prevent tumor seeding into the orbit, and then excising a long section of optic nerve for proper histopathological evaluation. 57 Following enucleation, an orbital implant is placed to provide the socket with enough volume and allow the 4 rectus muscles to attach for motility. Immediately after enucleation, fresh tissue should be harvested on a separate tray for genetic studies.
A corollary to enucleation is the adequate histopathological evaluation of globe pathology, because retinoblastoma with histological features signifying a high risk of metastasis requires adjuvant intravenous chemotherapy. 58 High-risk features include choroidal invasion, retrolaminar optic nerve invasion, scleral and orbital invasion, and anterior chamber invasion. An analysis of 1,020 study patients with high-risk features after enucleation showed that 24% of study volunteers at high risk developed metastasis if not treated with adjuvant chemotherapy, whereas 4% of these study patients had metastasis if treated with chemotherapy. 59 The regimen for adjuvant chemotherapy is vincristine/etoposide/carboplatin for 4 to 6 cycles.
External Beam Radiotherapy
External beam radiotherapy can be used to treat eyes unresponsive to other treatments, those with a tumor located at the optic nerve resection margin (36 Gy to orbit and 10 Gy boost to chiasm), and as treatment of extraocular retinoblastoma such as those extending through the sclera, orbit, or intracranially (40-45 Gy). 18 External beam radiotherapy is rarely used and employed only when necessary because of its subsequent risks. It is known to cause midfacial hypoplasia in young patients and increase the risk of development of soft-tissue sarcomas, brain tumors, osteosarcomas, and other cancers. 60 In patients with bilateral disease, the incidence of secondary malignancy at 50 years from diagnosis of retinoblastoma is 21% in patients who were not treated vs 38% for those who were treated with ra-diation. [61] [62] [63] If possible, any radiation (including radiography, computed tomography, and external beam) should be avoided in individuals with heritable retinoblastoma to minimize their lifetime risk of developing secondary cancers.
Extraocular Therapy
Although their incidence is rare in developed countries, cases of extraocular disease are occasionally seen in neglected or inadequately treated patients. 64, 65 Tumors may directly extend through emissary vessels of the sclera into the orbital soft tissue surrounding the eye. Treatment of orbital retinoblastoma includes systemic chemotherapy and external beam radiotherapy (40-45 Gy) with a rate of cure between 60% and 85%. 18 Treatment may also extend to the optic nerve into the brain and meninges with subsequent seeding of spinal fluid. Most recurrences occur in the central nervous system and are associated with a low cure rate; regimens proven to be effective include vincristine, cyclophosphamide, doxorubicin, and platinum as well as epipodophyllotoxin-based drugs.
66 No preclinical or clinical evidence supports the use of intrathecal chemotherapy. Craniospinal irradiation using 25 to 35 Gy is sometimes provided. Retinoblastoma may also hematogenously spread to the bone marrow, bones, lungs, or liver. For metastatic disease, multiple-agent, high-dose chemotherapy and autologous hematopoietic stem cell transplantation can be administered as rescue therapy. 67 The Children's Oncology Group developed a prospective, multi-institutional, international trial for metastatic retinoblastoma, and data will be available in early 2016; that study hopes to define differences in site of metastasis and outcome.
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Emerging Therapies
New developments in the treatment of retinoblastoma are geared toward an ideal system that is affordable and can easily be used by ophthalmologists or ocular oncologists -even those in developing nations -and is locally effective to the main tumor as well as tumor seeds, causes minimal complications, and can achieve a sustained treatment effect to retinoblastoma without spreading tumor cells. A sustained treatment effect is desired because, even when compounds do reach the target site, rapid clearance from the eye often results in short intraocular residence times. In addition, many patients with retinoblastoma are young children who oftentimes require sedation to receive intraocular therapy -sustained drug-release mechanisms will enable continuous medication dosing.
Preclinical models that accurately reflect human disease are needed for rare childhood cancers such as retinoblastoma because not enough patients exist for large-scale multicenter clinical trials. 8 Despite this lack of clinical trials, rates of patient survival and ocular preservation have improved. 7 Animal models remain instrumental in understanding biological mechanisms and designing targeted therapies for this disease. [8] [9] [10] Novel treatment options being explored in vitro and in vivo include alternative chemotherapeutic agents, molecularly targeted therapies, gene therapy, localized delivery, and the sustained-release of broad-spectrum chemotherapy agents.
Alternative Chemotherapeutic Agents
Topotecan, a topoisomerase inhibitor that works in the G0 phase of the cell cycle, may be used as a single agent or in combination with other agents for the treatment of retinoblastoma. Subconjunctival, sustained-release topotecan has been shown to decrease tumor burden in a transgenic mouse model of retinoblastoma. 69 In a similar fashion, periocular injections of topotecan in fibrin sealant in humans have been shown to achieve retinoblastoma tumor volume reduction. 70 Topotecan can also reduce retinoblastoma tumor burden when given systemically, 71 via IAC, 72 or via intravitreal injections. 43 When compared with standard chemotherapeutic agents used to treat retinoblastoma, topotecan avoids the retinal toxicity of melphalan, the nephrotoxicity of carboplatin, and the hematotoxicity of etoposide. 73 Topotecan is a good candidate drug for intravitreal injection because it has minimal retinal toxicity and achieves maximum concentration levels 50 times higher than systemic exposure. 73, 74 Our laboratory has shown that 20-µg topotecan can provide sustained retinoblastoma cell-line killing in vitro, 75 similar to the clinically demonstrated retinoblastoma cell-line killing ability with 20-µg intravitreal topotecan. 43 Anthracyclines are a class of chemotherapeutic drugs that inhibit topoisomerase and intercalate DNA. They are used to treat several cancers and are active against retinoblastoma; however, because of their limited blood-brain barrier penetration, their use is typically limited to extraocular and metastatic retinoblastoma. The anthracycline idarubicin has been shown to be effective against retinoblastoma tumor cells in bone marrow (response rate, 60%), but sufficient concentrations have not been achieved at target sites (eg, central nervous system).
76 A study to improve intraocular exposure of the anthracycline doxorubicin while also reducing systemic exposure to the drug was successful in maintaining sustained levels of doxorubicin after the intravitreal injection of the drug encapsulated in polyhydroxybutyrate microspheres in rabbits.
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Molecularly Targeted Therapy RB1 was the first tumor suppressor gene identified and cloned, yet no effective, molecularly targeted cure currently exists for retinoblastoma. 78 This could perhaps be attributed to the variety of unknown secondary mutations and differential expression of other genes aside from RB1 involved in tumorigenesis, as well as questions on the cellular origin of retinoblastoma. 79, 80 Significant progress has been made in our understanding of tumor biology, leading to the discovery and development of small molecules for the treatment of retinoblastoma, including novel, targeted therapeutics such as inhibitors of the MDMX-p53 response (nutlin-3a), histone deacetylase (HDAC) inhibitors, and spleen tyrosine kinase (SYK) inhibitors. 9, 81 Nutlin-3 is an imidazole analogue that plays a role in the activation of p53, a tumor suppressor protein.
It is a small molecule inhibitor of MDM2 and MDMX and prevents the association of both these proteins with p53. Studies have shown that nutlin-3 restores the p53 pathway in retinoblastoma cells lacking both retinoblastoma protein and p53 activity, thus inducing p53-mediated apoptosis. 82 Subconjunctival injection of nutlin-3 in mouse models of retinoblastoma resulted in reduced tumor burden when used in combination with topotecan, demonstrating a synergistic effect. 83 Nutlin-3 is being studied in phase 1 clinical trials for the treatment of retinoblastoma.
82,83
Although it is not expressed in normal human retinas, SYK was found to be upregulated in retinoblastoma tumor samples and has been shown to be required for retinoblastoma cell survival. 84 Inhibition of SYK with BAY-61-3606 and R406 caused cell death in retinoblastoma, and an in vivo study of orthotopic, xenograft mice showed that subconjunctival BAY-61-3606 was effective at blocking retinoblastoma cell proliferation. 84 In addition, studies of SYK inhibition have also implicated several downstream signaling molecules as mediators of SYK survival, including the B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) family of proteins. 85 Myeloid cell leukemia 1, a member of the BCL2 family, is a potential target because it is upregulated in retinoblastoma and is being developed as a therapy for other cancers. 86 Another class of targeted therapies in phase 1 clinical trials are the inhibitors of HDAC.
87 Cells with elevated E2F1 activity are uniquely sensitive to inhibitors of HDAC through the overexpression of proapoptotic factors. Cells lacking retinoblastoma protein have increased E2F1 activity, and retinoblastoma-derived cell lines have demonstrated particular sensitivity to apoptosis induced from inhibitors of HDAC. 88 In a preclinical trial, inhibitors of HDAC slowed the growth of retinoblastoma-derived tumors in both transgenic and xenograft murine models of retinoblastoma, with minimal off-target effects, suggesting that inhibitors of HDAC may specifically inhibit the proliferation of retinoblastoma tumor cells and, thus, have lower systemic toxicities relative to chemotherapeutic agents.
89
Gene Therapy Suicide gene therapy is based on the introduction of a viral or bacterial gene into tumor cells, thus allowing the conversion of a nontoxic compound into a lethal drug to kill the tumor cells. In a phase 1 study, intravitreal injections of an adenovirus vector containing HSVtk followed by treatment with ganciclovir were shown to be safe and effective against vitreous seeds.
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Although these results were promising, it may be unlikely that this type of gene therapy could be used as first-line treatment for retinoblastoma but rather its use may be better suited as an adjunct to standard therapy for the treatment of refractory vitreous seeds.
Local Drug-Delivery Systems Nanotechnology-based drug-delivery systems for the treatment of cancer have significantly evolved during the past decade by enabling options for site-specific delivery and increased bioavailability. 91 Investigations have been conducted on the potential use of different materials as intraocular drug carriers, such as biodegradable polyesters, dendrimers, liposomes, mesoporous silica, and gold nanoparticles. 91 These particles can be modified to target specific cells, and they can be designed to ensure sustained drug release to increase the therapeutic effectiveness of the drug molecules they contain. 92 Nanoparticle-based systems designed for the treatment of retinoblastoma have improved rates of drug delivery to the posterior segment of the eye and have increased the intravitreal half-life of chemotherapy agents, thus highlighting their potential in treatment of this cancer. 93 The intravitreal delivery of doxorubicin-loaded, polyester-based microspheres in the ocular tissue from rabbits exhibited reduced rates of toxicity to surrounding normal structures. 77 Dendrimer nanoparticles containing carboplatin significantly reduced tumor volume compared with free carboplatin in a retinoblastoma mouse model. 94 Polylactic glycolic acid nanoparticles developed to deliver doxorubicin 95 and etoposide 96 were tested on Y79 retinoblastoma cell lines and may be potential candidates for sustained drug-release models.
Gold-based nanoparticles have unique physical properties, including a strong ability to absorb near-infrared light, which enables the photothermal destruction of cancer cells. 97 Light-activated drug release can be attained using gold nanoparticles conjugated with chemotherapeutic agents. 98 For example, gold nanocages are encapsulated with a smart polymer, wherein the nanocages absorb light converted to heat, thus causing the collapse of the polymer and the subsequent release of doxorubicin. 99 The light-responsiveness of gold and other photosensitive nanocarriers infers considerable potential for ophthalmic conditions such as retinoblastoma because of the regular use of lasers in the treatment of retinal disease and the added benefit of facilitating the controlled timing and location of delivery of therapeutic agents. Gold nanoparticles can also cross the blood-retina barrier without significant rates of cytotoxicity. 100 The intravitreal injection of gold-tethered liposomes and viral-like nanoparticles containing topotecan is being investigated in a rabbit model of retinoblastoma that develops vitreous seeds. 55, 101 Another injectable agent being studied as a delivery system of chemotherapeutic agents for the treatment of retinoblastoma is the biodegradable carrier fibrin glue. 102 Carboplatin 103 and topotecan 69 released from fibrin depots have both been shown to retain their bioactivity against retinoblastoma cells in culture. Carboplatin released from a fibrin depot was also shown to decrease tumor burden in a transgenic murine model of retinoblastoma cells. 104 In another report, fibrin sealants sustained delivery of carboplatin in ocular tissues compared with carboplatin in plain solution, which clears rapidly in vivo. 105 Promising results have been reported for topotecan combined with fibrin in clinical studies.
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Suprachoroidal Injection Suprachoroidal injection with microneedles is a route of targeted drug delivery to the choroid and retina that poses minimal risk of extraocular tumoral spread, because the vitreous and subretinal spaces are not entered. In a rabbit model, bevacizumab was determined to be safe and effective when injected into the suprachoroidal space; high concentrations were found in the posterior segment tissues. 107 Microneedles are 0.8-to 1.0-mm long, 32-gauge needles with a short bevel that penetrate through the sclera into the supraciliary space. When the microneedle injects compounds into the supraciliary space, these compounds posteriorly spread into the suprachoroidal space. 108 In phase 1 clinical trials, microneedles for suprachoroidal injections have been used to inject triamcinolone into the suprachoroidal space in patients with uveitis and macular edema following retinal venous occlusion (NCT02303184, NCT01789320). The suprachoroidal delivery of chemotherapeutic agents is a promising approach for applications in retinoblastoma, and, ideally, will result in high choroidal and retinal concentrations targeted toward the elimination of subretinal seeds and the prevention of choroidal invasion, with minimal biodistribution and toxicity to surrounding tissue. Our laboratory is investigating the suprachoroidal and intravitreal injection of topotecan using microneedles in a rabbit model of retinoblastoma (Fig 2) . 5 
Conclusions
Management of retinoblastoma is individualized according to patient characteristics and preferences, with the main goals being to save the patient's life and to preserve useful vision, if possible. Therapeutic options for retinoblastoma have rapidly evolved in recent years, with a paradigm shift in standard treatment protocols toward the targeted delivery of chemotherapeutic agents. Increased use of intra-arterial and intravitreal types of chemotherapy with focal consolidation, along with the reduced use of systemic chemotherapy, enucleation, and external beam radiotherapy, has contributed to improved rates of survival and globe salvage while also minimizing unwanted treatment-related adverse events. However, these approaches are not without complications, and a need still exists to weigh the risks and benefits of treatment and to evaluate their long-term effects. New therapies being investigated include novel carriers and routes for local drug delivery as well as molecularly targeted therapies. Our under- standing of tumor biology and how to develop safe and effective therapy continues to progress, thus helping to ensure that retinoblastoma will be a curable childhood cancer worldwide in the future.
